Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moACETYLCYSTEINE (acetylcysteine) by Pfizer is overdose. Approved for lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in adults, greater with acute ingestion, from repeated supratherapeutic ingestion (rsi) (). First approved in 2007.
Drug data last refreshed 18h ago
overdose. Acetaminophen doses of 150 mg/kg or greater have been associated with hepatotoxicity. Acetylcysteine probably protects the liver by maintaining or restoring the glutathione levels, or by acting as an alternate substrate for conjugation with, and thus detoxification of, the reactive…
Worked on ACETYLCYSTEINE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Open Label
Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke
Oral N-acetylcysteine for Retinitis Pigmentosa
Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo